American Diabetes Association, “Standards of medical care in diabetes—2013,” Diabetes Care, vol. WEQAS has recently introduced a new Point of Care (POC) INR EQA control, suitable for use with the Abbott i-STAT, Roche CoaguChek XS, XS Plus & XS Pro and Siemens Xprecia Stride instruments.
Abaxis Level 1 Chemistry Controls produced specifically for use with the Piccolo xpressa„? by Randox. Abaxis Level 1 Chemistry Controls produced specifically for use with the Piccolo Xpress® by Randox. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.AbstractPoint-of-care (POC) glucose technology is currently considered to be insufficiently accurate for the diagnosis of diabetes. Point of care (POC, or near patient) testing for measurement of the international normalized ratio (INR) is extensively used for self-monitoring of oral anticoagulation in patients under anticoagulant therapy. The objective of this study was to investigate the diagnostic accuracy of an innovative, interference-resistant POC glucose meter (StatStrip glucose hospital meter, Nova Biomedical, USA) in subjects with a previous history of dysglycaemia, undergoing a 75 g diagnostic oral glucose tolerance test (oGTT). Weqas EQA samples retain the advantage of being liquid stable and ready to use, with no further treatment required to activate the product, thus ensuring quick and easy analysis for the POC end user. Venous and capillary blood sampling for the reference laboratory procedure (RLP) and POC-glucose measurement was carried out at fasting and 2 h oGTT, and categories of glucose tolerance were classified according to 2006 WHO diagnostic criteria for the respective sample type.

Bakris et al., “Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus,” Clinical Chemistry, vol. Gambino, “Glucose: a simple molecule that is not simple to quantify,” Clinical Chemistry, vol. Biljak, et al., “Implications of variable preanalytical procedures for the diagnosis of diabetes mellitus in Croatia,” Biochemia Medica, vol.
Haeckel, “Comparison of several point-of-care testing (POCT) glucometers with an established laboratory procedure for the diagnosis of type 2 diabetes using the discordance rate.
Simmons, “Point-of-care testing as a tool for screening for diabetes and pre-diabetes,” Diabetic Medicine, vol. Coleman et al., “Point-of-care testing of capillary glucose in the exclusion and diagnosis of diabetes in remote Australia,” Medical Journal of Australia, vol. Joshi et al., “Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India,” Diabetes Care, vol. Fogh-Andersen et al., “Approved IFCC recommendation on reporting results for blood glucose (abbreviated),” Clinical Chemistry, vol.
Scott et al., “Evaluation of the impact of hematocrit and other interference on the accuracy of hospital-based glucose meters,” Diabetes Technology and Therapeutics, vol.

Kwan, “Evaluation of a point-of-care glucose meter for general use in complex tertiary care facilities,” Clinical Biochemistry, vol. Car, “Performance of the StatStrip glucose meter in inpatient management of diabetes mellitus,” Diabetologia Croatica, vol. Cembrowski, “A review of standards and statistics used to describe blood glucose monitor performance,” Journal of Diabetes Science and Technology, vol. Thorpe, “Assessing the quality of publications evaluating the accuracy of blood glucose monitoring systems,” Diabetes Technology and Therapeutics, vol. Carstensen et al., “Comparability of venous and capillary glucose measurements in blood,” Diabetic Medicine, vol. Cardenas Jr., “Comparison of POCT and central laboratory blood glucose results using arterial, capillary, and venous samples from MICU patients on a tight glycemic protocol,” Clinica Chimica Acta, vol.

Gestational diabetes blood sugar levels too high 6.4
Blood sugar level 242


  1. 22.11.2014 at 13:46:16

    HbA1c does not identify exactly the same.

    Author: VERSACE
  2. 22.11.2014 at 22:47:14

    Important questions concerning diabetes and his manufacturers which make a wide range.

    Author: PORCHE
  3. 22.11.2014 at 17:24:46

    These subtle signs and i too have been diagnosed with 90% specificity compared with.

    Author: SeNsiZ_HaYaT_x
  4. 22.11.2014 at 20:17:22

    You can also limit based on pancreatic involvement: patients with blood sugar testing, meals, exercise.

    Author: KISSKA325